Diagnostic Utility and Pathogenic Implication of Circulating MicroRNAs in Reversible Cerebral Vasoconstriction Syndrome
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA607654 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR11119124.fastq.gz | Fastqsanger.gz | |||
| SRR11119125.fastq.gz | Fastqsanger.gz | |||
| SRR11119126.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 3 of 3 |
Similar Datasets
Project description:The pathophysiology of reversible cerebral vasoconstriction syndrome (RCVS) is elusive. We speculated that circulating miRNAs might participate in the pathogenesis of RCVS and could assist clinical diagnosis. We prospectively recruited 75 RCVS patients (including 20 in discovery cohort, 23 in validation cohort-1, and 32 in the validation cohort-2) together with 76 age- and sex-matched controls. Five miRNAs including miR-130a-3p, miR-130b-3p, let-7a-5p, let-7b-5p andlet-7f-5p were significantly upregulated in patients with RCVS during ictal stage in comparison with that in their remission stage or controls. The combined miRNA panel well differentiated patients from controls (area under curve of Receiver Operating Characteristic curve was 0.906, 0.890 and 0.867 in three different cohorts respectively.) The expression of miR-130a-3p was associated with disruption of blood-brain barrier. Target prediction and pathway enrichment analysis suggested that endothelin-1 (EDN1) and transforming growth factor-beta (TGF-β) signaling pathway might link these miRNAs to the pathogenesis of RCVS. In vitro functional validation in human umbilical vein endothelial cells (HUVEC), human blood-brain barrier cell line (hCMEC/D3 cells) and HEK 293 cells confirmed that EDN1 and genes (BMPR2, SMAD5 and TGFBR2) involved in TGF-β signaling pathway were downregulated by these miRNAs. These miRNAs were correlated with plasma endothelin-1 level in the controls but not patients, indicating a deregulated feedback loop in patients during the disease state. To conclude, we identified the miRNA signatures associated with RCVS, which revealed excellent diagnostic performance, clinical relevance, and were functionally relevant to the putative pathomechanisms.
2023-02-19 | GSE145581 | GEO
Project description:Exploring the utility of circulating miRNAs as diagnostic biomarkers of fasciolosis
| PRJNA1068587 | ENA
Project description:Sequence-based genetic testing identifies causative variants in ~50% of individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA methylation are implicated in various neurodevelopmental disorders but remain unstudied in DEEs. We interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral blood samples from 582 individuals with genetically unsolved DEEs. We identify rare differentially methylated regions (DMRs) and explanatory episignatures to uncover causative and candidate genetic etiologies in 12 individuals. Using long-read sequencing, we identify DNA variants underlying rare DMRs, including one balanced translocation, three CG-rich repeat expansions, and four copy number variants. We also identify pathogenic variants associated with episignatures. Finally, we refine the CHD2 episignature using an 850K methylation array and bisulfite sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate variants as 2% (12/582) for unsolved DEE cases.
2024-06-13 | GSE269416 | GEO
Project description:Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients with Diffuse Glioma
| PRJNA578115 | ENA
Project description:Diagnostic Utility of DNA Methylation Analysis in Genetically Unsolved Pediatric Epilepsies and CHD2 Episignature Refinement
| PRJNA1121606 | ENA
Project description:Effective management and control of parasitic infections on farms depends on their early detection. Traditional serological diagnostic methods for Fasciola hepatica infection in livestock are specific and sensitive, but currently the earliest detection of the parasite only occurs at approximately three weeks post-infection. At this timepoint, parasites have already entered the liver and caused the tissue damage and immunopathology that results in reduced body weight and loss in productivity. Here, we investigated whether the differential abundance of micro(mi)miRNAs in sera of F. hepatica-infected sheep has potential as a tool for the early diagnosis of infection. Using miRNA sequencing analysis, we discovered specific profiles of sheep miRNAs at both the pre-hepatic and hepatic infection phases in comparison to non-infected sheep. In addition, six F. hepatica-derived miRNAs were specifically identified in sera from infected sheep. Thus, a panel of differentially expressed miRNAs comprising four sheep (miR-3231-3p; miR133-5p; 3957-5p; 1197-3p) and two parasite miRNAs (miR-124-3p; miR-Novel-11-5p) were selected as potential biomarkers. The expression of these candidates in sera samples from longitudinal sheep infection studies collected between 7 days and 23 weeks was quantified using RT-qPCR and compared to samples from age-matched non-infected sheep. We identified oar-miR-133-5p and oar-miR-3957-5p as promising biomarkers of fasciolosis, detecting infection as early as 7 days. The differential expression of the other selected miRNAs was not sufficient to diagnose infection; however, our analysis found that the most abundant forms of fhe-miR-124-3p in sera were sequence variants (IsomiRs) of the canonical miRNA, highlighting the critical importance of primer design for accurate diagnostic RT-qPCR. Accordingly, this investigative study suggests that certain miRNAs are biomarkers of F. hepatica infection and validates miRNA-based diagnostics for the detection of fasciolosis in sheep.
2024-04-15 | GSE254115 | GEO
Project description:Reversible p53 activation using a temperature variant of p53
2012-04-30 | E-MEXP-3224 | biostudies-arrayexpress
Project description:We investigated the diagnostic value and pathophysiological role of circulating microRNA (miR) in vasospastic angina (VA). We enrolled patients who underwent coronary angiography for chest pain to explore the miR's diagnostic utility. In addition, we investigated the role of miRs in regulating endothelial nitric oxide synthase (eNOS) expression in human coronary artery endothelial cells (hCAECs). Among the 121 patients, 46 were diagnosed with VA (VA group), 26 with insignificant coronary lesions (ICL group), and 49 with atherothrombotic angina (AA group). The VA group showed a significantly higher expression of miR-17-5p, miR-92a-3p, and miR-126-3p than the ICL group. In contrast, miR-221-3p and miR-222-3p were upregulated in the AA group compared to the VA group, and all levels of miR-17-5p, miR-92a-3p, miR-126-3p, miR-145-5p, miR-221-3p, and miR-222-3p differed between the AA group and the ICL group. In the hCAECs, transfection with mimics (pre-miR) of miR-17-5p, miR-92a-3p, and miR-126-3p was associated with eNOS suppression. Additionally, transfection with inhibitors (anti-miR) of miR-92a-3p significantly rescued the eNOS suppression induced by lipopolysaccharide. In conclusion, the circulating miRs not only proved to have diagnostic utility, but also contributed to pathogenesis by eNOS regulation.
| S-EPMC7290712 | biostudies-literature
Project description:Utility analyses of AVITI sequencing platforms
| PRJNA1034957 | ENA
Project description:The standard of care for first-tier clinical investigation of the etiology of congenital malformations and neurodevelopmental disorders is chromosome microarray analysis (CMA) for copy number variations (CNVs), often followed by gene(s)-specific sequencing searching for smaller insertion-deletions (indels) and single nucleotide variant (SNV) mutations. We compared diagnostic rate of WGS to CMA and targeted gene testing of 100 patients referred to The Hospital for Sick Children Genetics clinic in 2014. WGS identified genetic variants meeting clinical diagnostic criteria in 34% of cases, representing a 4-fold increase in diagnostic rate over CMA (8%) (p-value = 1.42e-05) alone and >2-fold increase in CMA plus targeted gene sequencing (13%) (p-value = 0.0009). WGS identified all rare clinically significant CNVs that were detected by CMA. In an additional 26 patients, WGS revealed indel and missense mutations presenting in a dominant (63%) or a recessive (37%) manner. We found four subjects with mutations in at least two genes associated with distinct genetic disorders, including two cases harboring a pathogenic CNV and SNV. When considering medically actionable secondary findings in addition to primary WGS findings, 38% of patients would benefit from genetic counselling.
| EGAS00001001623 | EGA